BioNTech SE (BNTX) Payables (2018 - 2026)

BioNTech SE has reported Payables for 8 years, with the latest figure at $622.6 million in Q4 2025.

• Quarterly Payables rose 36.55% year-over-year to $622.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $622.6 million (up 36.55% YoY) and the FY2025 annual result came in at $604.3 million, up 32.54% from the prior year.
• Payables grew to $622.6 million in Q4 2025 per BNTX's latest filing, from $467.4 million in the prior quarter.
• Over five years, Payables peaked at $949.3 million in Q2 2024 and troughed at $34.3 million in Q1 2023.
• A 5-year average of $439.3 million and a median of $434.7 million in 2021 frame the typical range for Payables.
• The sharpest annual moves came in 2021 and 2023: Payables soared 1829.06% in 2021, then sank 89.04% in 2023.
• Over 5 years, Payables stood at $527.9 million in 2021, then sank by 60.15% to $210.4 million in 2022, then surged by 82.23% to $383.4 million in 2023, then rose by 18.94% to $456.0 million in 2024, then soared by 36.55% to $622.6 million in 2025.
• According to Business Quant data, Payables over the past three periods registered $622.6 million, $467.4 million, and $570.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.